ETX.L - e-Therapeutics plc

LSE - LSE Delayed price. Currency in GBp

e-Therapeutics plc

17 Blenheim Office Park
Long Hanborough OX29 8LN
United Kingdom
44 1993 880 000

Full-time employees18

Key executives

NameTitlePayExercisedYear born
Dr. Raymond BarlowCEO & Director435kN/A1969
Mr. Steven MedlicottCFO, Fin. Director & Exec. Director287kN/A1965
Mr. Jonny WrayHead of Discovery InformaticsN/AN/AN/A
Mr. Colin StubberfieldHead of Drug DiscoveryN/AN/AN/A
Mr. Alan WhitmoreHead of Discovery BiologyN/AN/AN/A
Amounts are as of 31 December 2019, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.


e-Therapeutics plc engages in the discovery of drugs through its proprietary network-driven drug discovery platform in the United Kingdom. It is developing two NDD-derived immuno-oncology programs, including tryptophan catabolism and immune checkpoint modulation. The company, through its subsidiary, Searchbolt Limited, develops search engine technology. The company has collaborations with C4X Holdings PLC, Intellegens, Biorelate, and Novo Nordisk. e-Therapeutics plc was founded in 2001 and is based in Long Hanborough, the United Kingdom.

Corporate governance

e-Therapeutics plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.
By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more